Originally published In Press as doi:10.1074/jbc.M110867200 on March 7, 2002
J. Biol. Chem., Vol. 277, Issue 20, 17502-17510, May 17, 2002
Characterization of the Acid Stability of Glycosidically Linked
Neuraminic Acid
USE IN DETECTING DE-N-ACETYL-GANGLIOSIDES IN HUMAN
MELANOMA*
Justin L.
Sonnenburg,
Herman
van Halbeek, and
Ajit
Varki
From the Glycobiology Research and Training Center, Departments of
Medicine and Cellular and Molecular Medicine, University of California,
San Diego, La Jolla, California 92093-0687
Received for publication, November 13, 2001, and in revised form, March 1, 2002
 |
ABSTRACT |
The glycosidic linkage of sialic
acids is much more sensitive to acid hydrolysis than those of other
monosaccharides in vertebrates. The commonest sialic acids in nature
are neuraminic acid (Neu)-based and are typically
N-acylated at the C5 position. Unsubstituted Neu is thought
to occur on native gangliosides of certain tumors and cell lines, and
synthetic de-N-acetyl-gangliosides have potent biological
properties in vitro. However, claims for their natural existence are based upon monoclonal antibodies and pulse-chase experiments, and there have been no reports of their chemical detection. Here we report that one of these antibodies shows
nonspecific cross-reactivity with a polypeptide epitope, further
emphasizing the need for definitive chemical proof of unsubstituted Neu
on naturally occurring gangliosides. While pursuing this, we found that
2-3-linked Neu on chemically de-N-acetylated
GM3 ganglioside resists acid hydrolysis under conditions
where the N-acetylated form is completely labile. To
ascertain the generality of this finding, we investigated the stability
of glycosidically linked
- and
-methyl glycosides of Neu. Using
NMR spectroscopy to monitor glycosidic linkage hydrolysis, we find that
only 47% of Neu
2Me is hydrolyzed after 3 h in 10 mM HCl at 80 °C, whereas Neu5Ac
2Me is 95% hydrolyzed
after 20 min under the same conditions. Notably, Neu
2Me is
hydrolyzed even slower than Neu
2Me, indicating that acid resistance
is a general property of glycosidically linked Neu. Taking advantage of
this, we modified classical purification techniques for
de-N-acetyl-ganglioside isolation using acid to first
eliminate conventional gangliosides. We also introduce a phospholipase-based approach to remove contaminating phospholipids that
previously hindered efforts to study
de-N-acetyl-gangliosides. The partially purified sample can
then be N-propionylated, allowing acid release and mass
spectrometric detection of any originally existing Neu as Neu5Pr. These
advances allowed us to detect covalently bound Neu in lipid extracts of
a human melanoma tumor, providing the first chemical proof for
naturally occurring de-N-acetyl-gangliosides.
 |
INTRODUCTION |
Gangliosides are amphipathic glycosphingolipids that are mostly
found in the outer leaflet of the plasma membrane (1-4). They are
typically characterized by the presence of at least one sialic acid
residue and a lactosyl ceramide core. Other features of a ganglioside
oligosaccharide moiety, such as the number and branching pattern of
monosaccharides and modifications such as O-acetylation, are
regulated in a tissue-specific and temporal manner. The role of
gangliosides in cell signaling (5-9) and cell-cell and cell-matrix
interactions (10-13) and host-pathogen interactions (14-16) has been
extensively studied and is largely dictated by the structure of the
glycan component.
Most sialic acids on gangliosides share a core neuraminic acid
(Neu)1 structure and are
N-acylated at the C-5 position with either an
N-acetyl or an N-glycolyl group (giving Neu5Ac or
Neu5Gc, respectively). It was originally thought that unsubstituted
glycosidically linked Neu did not occur in nature (17). However, there
have been several reports suggesting its presence in gangliosides (5,
7, 18-21) and more recently in mucin-type glycoproteins (22, 23).
Hakomori and colleagues (5) first defined
de-N-acetyl-gangliosides by suggestive evidence for a Neu
residue that was presumed to have arisen from
de-N-acetylation of Neu5Ac. A possible role of such gangliosides in signaling was also suggested based on the finding that
synthetic
de-N-acetyl-GM32
specifically enhanced epidermal growth factor receptor signaling when
added to cells in culture, whereas the conventional
N-acetylated GM3 had the opposite effect (5).
However, proof for the natural occurrence of this monosialoganglioside
was based upon the reactivity of a monoclonal antibody (mAb) DH5 that
could recognize the synthetic molecule.
In related studies, our group used radiolabeling and pulse-chase
techniques to indicate that ganglioside sialic acids were undergoing a
de-/re-N-acetylation cycle in cultured human melanoma cells
(18). In collaboration with Tai's group (19), we also described
monoclonal antibody SGR37 raised against synthetic
de-N-acetyl-GD3, which was used to suggest that
this disialoganglioside is specifically expressed in some human
melanomas and lymphomas (20).
Despite all of these suggestive reports, no one has provided definitive
structural proof for the natural existence of
de-N-acetyl-gangliosides. Although Hidari et al.
(21) provided 1H NMR data defining traces of
de-N-acetyl-GM1 in bovine brain gangliosides, these preparations had been subjected to alkaline saponification for phospholipid degradation under conditions that would
have caused some chemical de-N-acetylation. Previous
attempts to purify de-N-acetyl-gangliosides from natural
sources have also been unsuccessful. Contaminating molecules in total
lipid extracts, such as phospholipids and more abundant N-acylated
gangliosides, can interfere with purification and detection by mAbs.
Additionally, cell lines and cell line-based tumors have proven to be
unreliable sources of de-N-acetyl-gangliosides because the
expression level based on monoclonal antibody detection is low and
variable. Furthermore, as reported here, at least one of these mAbs
shows nonspecific cross-reactivity to a peptide.
In unrelated studies we have reported an acid-stable, mono-carboxylated
modification of as yet unknown structure on the N-linked glycans of bovine lung (24, 25). In seeking to understand the nature of
this carboxylated moiety, we considered the possibility that it might
be a modified type of sialic acid. It is known that the glycosidic
linkage of amino sugars like glucosamine is more stable to acid
hydrolysis when the amino group is unsubstituted (26). Although sialic
acids are generally among the most acid labile of glycosidically linked
sugars, we considered the possibility that the glycosidic linkage of
Neu with its unsubstituted amino group might be acid-resistant. As it
turned out, the carboxylate in question was not part of a sialic acid,
and further studies are currently under way to define its true nature.
However, in the course of exploring this issue, we discovered that the
glycosidic linkage of Neu is indeed quite resistant to acid. Employing
this knowledge, we report here a new approach for detection of
naturally occurring Neu in de-N-acetyl-gangliosides.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Hybridoma cells secreting mAbs SGR37 or SMR36
were prepared in collaboration with Dr. Tadashi Tai as previously
described (19). Expired clinical grade mAb R24 (Celltech Ltd.) (27) was
obtained from the National Cancer Institute; mAb DH2 (28) was kindly
provided by Dr. Sen-itiroh Hakomori. All hybridomas were cultured in
RPMI 1640, 10% heat-inactivated fetal calf serum, 1 ng/ml IL-6. B16
mouse melanoma cells were maintained in Dulbecco's modified Eagle's
medium (regular glucose), 10% heat-inactivated fetal calf
serum, and human U937 cells in RPMI 1640, 10% heat-inactivated fetal
calf serum. Chinese hamster ovary (CHO) cells (K1 strain) were cultured
in
-minimum essential medium, with 10% heat-inactivated fetal calf
serum. Human tissue samples were kindly provided by Dr. Nissi Varki
through the University of California, San Diego Cancer Center Histology
Core Service. Neu5Ac
2Me was purchased from Sigma, and Neu
2Me was
purchased from ICN Biomedicals. Unless otherwise stated, all other
chemicals were of reagent grade or higher and purchased from commercial sources.
Ganglioside De-N-acetylation--
Synthetic
de-N-acetyl-gangliosides were prepared as described (19, 29,
30). Briefly, 1 mg of GM3 or GD3 (Matreya) was dissolved in 14.3 ml of 1 M tetramethylammonium hydroxide
in butanol and heated to 100 °C in an oil bath for 3 h with
constant stirring. After adding 175 ml of water, the solution was
neutralized with 14.3 ml of 1 M acetic acid and dried on a
rotary evaporator. Small volumes of water were added throughout to
ensure complete evaporation of butanol. The
de-N-acetyl-gangliosides were recovered after dialysis and
lyophilization, dissolved in methanol, and stored at -20 °C. The
extent of de-N-acetylation was determined by high performance thin layer chromatography (HPTLC) to be ~50%.
Immunohistochemistry of CHO Cells--
CHO cells were plated on
tissue culture slide chambers (LabTek) and grown to 70-90%
confluence. The media was removed, and cells were washed once in PBS
and fixed in 2% paraformaldehyde in PBS for 30 min. Blocking was
performed by incubating the slides in PBS containing 1% bovine serum
albumin, and 3% goat serum for 30 min. Slides were incubated with
primary antibody solutions for 30 min. Primary antibodies included R24
(5 µg/ml final) and SGR37 (50% solution of hybridoma supernatant)
and were prepared in the same solution that had been used for blocking.
Slides were washed three times with PBS, and the horseradish-conjugated
secondary antibody was added (goat-anti-mouse IgG-horseradish
peroxidase; 1:50) in PBS. Slides were washed again in PBS 3 times and
developed using the AEC (3-amino-9-ethylcarbazole) substrate system
(Vector Labs). The substrate solution was removed, slides were washed twice, and nuclei were counterstained with hematoxylin. Images were
captured using the 40× objective on a Zeiss Axiophot microscope fitted
with a Sony DKC-5000 using NIH Image software.
Western Blot Analysis of CHO and Melur Cell
Polypeptides--
CHO and Melur cells were grown to 80% confluence in
large culture dishes (15-cm diameter) and harvested using a cell
scraper. 30 million cells were washed in PBS twice, and 300 µl of
reducing SDS-PAGE sample buffer was added. DNA was sheared by repeated pipetting using a 20-guage needle. The samples were boiled at 100 °C
for 5 min followed by a 5-min spin at 15,000 × g. 10 µl of the samples were used per lane on a 7.5% SDS-PAGE that was subsequently run at 100 V for approximately 1 h. The proteins in
the gel were transferred to a polyvinylidene difluoride membrane at 50 V for 3 h. Scissors were used to cut the membrane for separation of each lane. Strips of polyvinylidene difluoride were rocked gently in
either 2 mM sodium periodate in PBS for 30 min at 4 °C
(mild periodate) or 25 mM sodium periodate in 0.1 M sodium acetate buffer, pH 5.0, for 30 min at room
temperature (strong periodate) or left untreated. After washing the
periodate-treated lanes in PBS, all strips were soaked in blocking
buffer (PBS, 1% powdered milk) to block nonspecific binding sites.
Primary antibodies R24 (10 µg/ml) and SGR37 (50% hybridoma
supernatant) were diluted in blocking buffer and incubated with the
polyvinylidene difluoride strips for 1 h. The polyvinylidene
difluoride strips were washed 3 times for 5 min and incubated with the
alkaline phosphatase-conjugated secondary antibody (Goat-anti-mouse
IgG-AP; 1:4000) in blocking buffer. After three washes, the blots were developed using the alkaline phosphatase-conjugate substrate system (Bio-Rad).
Enzyme-linked Immunosorbent Assay (ELISA)--
Aliquots of
gangliosides (600 ng/well) in methanol were added to wells of 96-well
plates (NUNC) and allowed to dry overnight at room temperature. All
washes and incubations were performed at room temperature in ELISA
buffer (PBS, 1% bovine serum albumin). Nonspecific binding sites were
blocked with ELISA buffer for 2 h followed by a 2-h primary
antibody incubation. Primary antibodies used include DH2 (hybridoma
supernatant) and SMR36 (ammonium sulfate precipitate in 50% saturated
salt solution). mAbs were titrated to determine the optimal dilution.
Wells were washed 3 times for 5 min each in ELISA buffer before a 1-h
incubation with secondary antibody conjugated to horseradish peroxidase
(1:4000) (goat-anti-mouse IgG DH2; goat-anti-mouse IgM for SMR36)
(Bio-Rad). Wells were washed again 3 times for 5 min each and developed
in citrate phosphate buffer, pH 5.0, containing 400 µg/ml
o-phenylenediamine and 0.12% hydrogen peroxide. Reactions
were allowed to proceed for several minutes until a yellow color was
visible and then quenched with the addition of 1/3 volume 9 M sulfuric acid. Absorbance was measured at 490 nm on a
SpectraMax-250 96-well plate reader (Molecular Devices).
HPTLC--
Samples in methanol were applied 1 cm above the
bottom of an activated silica gel 60 glass-backed HPTLC plate (Merck)
using a 1-µl Hamilton syringe (4 µg of ganglioside/lane;
phospholipid extract originating from 2 × 106 B16 cells/lane).
Plates were developed in glass TLC tanks pre-equilibrated with
chloroform:methanol:water (65:25:4) for phospholipid separation or
chloroform, methanol, 0.02% CaCl2 (60:40:9) for separation
of gangliosides. Phospholipids were visualized using phosphomolybdate
spray reagent (Sigma) according to the manufacturer's directions.
Individual gangliosides were visualized using the appropriate
monoclonal antibody in an immuno-overlay assay.
Immuno-overlay--
This procedure was performed as described
elsewhere (19, 31). Briefly, HPTLC plates were allowed to air dry after
development and then plasticized by immersing the plate for 1 min in
hexane, 2% polyisobutylmethacrylate in chloroform (84:16). The plate
was allowed to air dry, placed horizontally in a humidified chamber, covered with primary antibody in overlay buffer (PBS, 1% bovine serum
albumin), and incubated at 4 °C overnight. Antibodies were used as
described for ELISA. After primary antibody incubation, the surface of
the plate was washed with overlay buffer 3 times for 5 min each and
then covered with a 1:1000 dilution of secondary antibody. Secondary
antibodies were identical to those used for ELISAs. The secondary
incubation was allowed to proceed at room temperature for 1 h.
After three 5-min washes, the gangliosides were visualized using 400 µg/ml o-phenylenediamine in citrate phosphate buffer, pH
5.0, with 0.12% hydrogen peroxide. Once bands were visible, plates
were rinsed with water and dried with a blow drier.
Lipid Extraction--
Tissue samples were sliced into small
pieces with a scalpel and homogenized in 10 mM HEPES, pH
7.4, using a Polytron homogenizer (Brinkmann Instruments). Ten volumes
of chloroform:methanol (1:1) were added, samples were sealed under
nitrogen gas, and the extraction was allowed to proceed at room
temperature for 12 h with gentle agitation. Protein precipitates
were pelleted by centrifugation (10,000 × g for 15 min), supernatants were collected and stored at 4 °C under nitrogen,
and the extraction was repeated using the same volume of
chloroform:methanol (1:1). The organic extracts were pooled and dried
under a stream of nitrogen.
Phospholipase Treatment--
Dried lipids were resuspended in 50 mM potassium phosphate buffer, pH 7.4, using probe
sonication and/or bath sonication. Phospholipase C (PLC) (Sigma;
P-9439) was added at 5 milliunits/mg of tissue extracted and incubated
with vigorous agitation at 37 °C in 3-h increments until degradation
was complete (as determined by HPTLC, showing that excess PLC failed to
further degrade a test aliquot of a given sample).
N-Acylation with Acyl Anhydrides--
Dry samples containing
known or putative de-N-acetyl sialic acids were dissolved in
saturated sodium bicarbonate and treated with 3.3% acetic anhydride or
propionic anhydride for 15 min at room temperature. An identical
mixture of sodium bicarbonate and the acyl anhydride was added 2 more
times and allowed to react for 15 min each time. Samples were
neutralized by adding an appropriate volume of 1 M HCl.
Control samples contained amounts of acetic or propionic acids
equivalent to the amounts of the anhydride used.
Analysis of Free Sialic Acids by 1,2-Diamino-4,5-methylene
Dioxybenzene (DMB) Derivatization and HPLC Analysis--
Samples
containing native or chemically acylated sialic acids were incubated at
80 °C for 3 h in 2 M acetic acid. In some cases,
samples were then passed over a cation exchange column (Dowex AG50W-X2,
H+ form), and the resulting volatile acids were removed by
lyophilization. Free sialic acids from some samples were finally bound
to an anion exchange column (Dowex AG1-X8, formate form) (Bio-Rad),
eluted with 1 M formic acid, and lyophilized to remove the
acid. Aliquots of free sialic acids were derivatized in 8 mM DMB, 1.5 M acetic acid, 0.8 M
-mercaptoethanol, 14 mM sodium hydrosulfite for 2.5 h at 50 °C in the dark (32). DMB-derivatized sialic acids were
resolved using a reverse phase C18 Microsorb-MV column (Varian, 4.6-mm
internal diameter × 25 cm, 5 µm) on a Rainin Dynamax SD-200
HPLC. Samples were eluted at a flow rate of 0.9 ml/min using either a
50-min isocratic elution in 8% acetonitrile, 7% methanol in water or
a 70-min isocratic elution in 7% acetonitrile, 7% methanol in water.
A Spectrovision FD-300 on-line fluorescence detector was used to
visualize the sialic acid derivatives as they eluted (excitation at 373 nm, emission at 448 nm).
Mass Spectrometric Analysis of DMB Derivatives--
DMB
derivatives of sialic acids were validated by mass spectrometry.
Fractions eluting from the C18 column were collected based on the
elution position of known standards, dried down using a speed-vac
and/or shaker-evaporator and stored in the dark. The fractions were
reconstituted in water and run on a Finnigan MAT HPLC with online Mass
Spectrometer model LCQ-Mass Spectrometer System. A Varian C18
column was used and eluted at 0.9 ml/min in the isocratic mode with 8%
acetonitrile, 7% methanol, and 0.1% formic acid in water over 50 min.
The eluant was simultaneously monitored by absorbance at 373 nm and by
electrospray ionization (ESI) mass spectrometry. The following ESI
settings were used. Capillary temperature was set at 210 °C, the
capillary voltage was set at 31 V, and the lens offset voltage set at 0 V. The spectra were acquired by scanning from m/z
150-2000 in the positive-ion mode. Tandem mass spectrometry spectra
were acquired by selecting the parent mass and using a 20% normalized
collision energy. Data analysis was performed using the Xcalibur data
analysis program from the instrument manufacturer.
Synthesis of Neu
2Me--
De-N-acetylation of
Neu5Ac
2Me was accomplished using hydrazine. Two micromoles of
lyophilized Neu5Ac
2Me were dissolved in 0.2-0.3 ml anhydrous
hydrazine, capped tightly in a nitrogen atmosphere, and incubated at
100 °C for 6 h. To remove the hydrazine, the sample was brought
to room temperature, uncapped, and placed in an evacuated chamber
containing a beaker of concentrated sulfuric acid and allowed to sit
overnight. After hydrazine evaporation, 0.2 ml of toluene was added to
the sample twice and blown off under a stream of nitrogen. The sample
was resuspended in 0.5 ml of water, and Neu
2Me was separated from
surviving Neu5Ac
2Me by loading onto a 0.5-ml column of Dowex
AG50W-X2 (H+ form) resin, washing with 2 ml of water, and eluting the
de-N-acetylated material with 2 ml of 1 M HCl.
The HCl was evaporated using a shaker-evaporator, and the sample was
resuspended in water and stored at -20 °C.
NMR Spectroscopy--
Solutions of methyl glycosides (~100
nmol) in D2O (0.7 ml; 99.9% D; Aldrich) were transferred
into 5-mm NMR tubes (Wilmad; 528PP), acidified with HCl in
H2O (a few µl) to the desired molarity (i.e.
pH), and sealed. The pH of the stock solutions (without the glycosides)
was measured using a Corning 240 pH meter. Time courses of glycoside
hydrolysis were monitored discontinuously as follows. The tubes were
placed in a water bath at 80 °C and removed for NMR analysis at
specified time points. The time that samples spent at room temperature
during NMR data collection or between 80 °C incubations was
determined to be insignificant with regard to sample degradation. NMR
experiments were carried out using a 500-MHz Varian Unity Inova
spectrometer controlled by a SUN MicroSystems Ultra-10 computer running
Varian VNMR software (version 6.1B). 1H NMR spectra were
acquired at 27 °C in 512 transients each; the samples were not spun.
The residual HDO signal was suppressed by low power presaturation. Data
processing included line-broadening (lb = 0.5) and zero-filling
(from 16 K to 32 K complex points) before Fourier transformation
followed by base-line correction and integration. Chemical shifts (
)
are reported relative to TSP-d4 (sodium
3-(trimethylsilyl)-propionate-2,2,3,3-d4)
(Aldrich); chemical shifts were actually measured using acetic acid
(
2.081 ppm at pH < 4) or acetone (
2.217 ppm;
pH-independent) as internal standards.
 |
RESULTS AND DISCUSSION |
A Monoclonal Antibody against a De-N-acetyl-ganglioside Shows
Nonspecific Cross-reactivity with Peptide Epitopes--
All prior
reports of detection of de-N-acetylated gangliosides have
used monoclonal antibodies. However, data using such antibodies cannot
be considered definitive, since reactivity can be abrogated by
interfering molecules (e.g.
phospholipids).3
Additionally, antibodies directed against carbohydrates can sometimes show nonspecific cross-reactivity with other epitopes. Indeed, we have
observed such cross-reactivity when staining CHO cells with mAb SGR37,
which was thought to be specific for
de-N-acetyl-GD3 (20). CHO cells do not express
GD3, the most likely precursor of
de-N-acetyl-GD3 (33). Despite this, the
cytoplasm of CHO cells was highly positive when stained with mAb SGR37
(Fig. 1A). The lack of
GD3 expression and the cytoplasmic localization of the
SGR37 reactivity suggested that the antibody was cross-reacting with
another epitope in the CHO cells. To further examine the nature of the
CHO cell reactivity, we performed a Western blot on an SDS-PAGE of CHO
cell extracts using anti-ganglioside mAbs. Although antibody R24
against GD3 did not bind to any of the CHO cell proteins,
SGR37 reacted with two major bands (Fig. 1B, lane 3). Reactivity was not lost even after harsh periodate treatment (Fig. 1B, lane 5), indicating that the
cross-reactive epitope is not even carbohydrate-dependent
and likely represents polypeptide mimicry of the antibody epitope. The
human melanoma cell line Melur, which has shown variable reactivity to
SGR37, was subjected to the identical Western blotting procedure but
did not shown this cross-reactivity of SGR37 to proteins (data not
shown). These observations of SGR37 cross-reactivity with a CHO cell
polypeptide further emphasizes the need for definitive chemical
evidence to prove that de-N-acetyl-gangliosides do exist in
nature.

View larger version (120K):
[in this window]
[in a new window]
|
Fig. 1.
Cross-reactivity of mAb SGR37 with
polypeptide epitopes in CHO cells. Panel A, immunostaining
of fixed CHO cells with mAbs R24 or SGR37. Note that the nuclei of all
cells were visualized with the general stain hematoxylin. Panel
B, Western blot of SDS-PAGE-separated polypeptides from CHO cells.
Lanes were either untreated (lanes 1-3), treated with mild
periodate (lane 4), or treated with strong periodate
(lane 5) before incubation without primary antibody
(lane 1), with R24 (lane 2), or with SGR37
(lanes 3-5). )
|
|
Neuraminic Acid in De-N-acetylated GM3 Is Resistant to
Mild Acid Hydrolysis--
In the course of studying a novel
acid-resistant carboxylated structure of N-linked glycans of
bovine lung (24, 25), we explored the possibility that it might be Neu.
Although this hypothesis turned out to be incorrect, our studies led to
novel findings regarding the acid stability of the Neu glycosidic
linkage. Here, we use the mAbs SMR36 (19, 20) and DH2 (28), which
recognize de-N-acetyl-GM3 and GM3,
respectively, to explore this question (antibody specificity is not an
issue when using purified standards). A mixture of the
monosialoganglioside GM3 (with a terminal Neu5Ac residue)
and chemically de-N-acetylated GM3 (with a
terminal Neu residue) was incubated at 80 °C for 3 h in either
water or 2 M acetic acid ("mild acid"-treated). After
evaporation of the solvent and resuspension of the residue in methanol,
aliquots of the solutions were spotted onto a 96-well plate in
triplicate, and an ELISA assay was performed with the aforementioned
monoclonal antibodies, as described under "Experimental
Procedures." As expected, the mild acid treatment, which is known to
be sufficient to completely hydrolyze the acid-sensitive glycosidic
linkage of Neu5Ac (34), resulted in complete loss of DH2 reactivity
(Fig. 2A). The lability of the
glycosidic linkage of Neu5Ac is emphasized by the loss of DH2
reactivity even after heating in water; cleavage of the Neu5Ac
2,3Gal
linkage under these conditions is attributed to "auto-hydrolysis,"
catalyzed by H+ ions from the Neu5Ac carboxyl group. In contrast, the
SMR36 reactivity decreased only slightly upon mild acid treatment,
indicating that the Neu
2,3Gal glycosidic linkage was relatively
resistant to acid hydrolysis under these conditions (Fig.
2A). This result is representative of several similar
experiments in which the difference in SMR36 reactivity between control
and acid-treated samples varied from no change to a 30% loss in
signal. The discrepancy is likely due to variable ganglioside recovery
after the mild acid treatment. A better quantitation of the relative
acid stability of the glycosidic linkages of Neu5Ac and Neu is shown
below using NMR on model compounds.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 2.
Acid stability of neuraminic acid in
de-N-acetyl-GM3. Panel A,
ELISA performed on a mixture of GM3 and
de-N-acetyl-GM3 that was untreated (black
bars) or incubated for 3 h at 80 °C in water (white
bars) or for 3 h at 80 °C in 2 M acetic acid
(gray bars) before application to ELISA plates. Monoclonal
antibodies used are indicated. Panels B and C,
HPTLC immuno-overlay of GM3 and
de-N-acetyl-GM3 (DeNAc-GM3)
using monoclonal antibodies DH2 and SMR36, respectively. Gangliosides
were incubated in water (W) or 2 M acetic acid
(A) at 80 °C for 3 h or were untreated
(U) before HPTLC plate application.
|
|
In a parallel experiment, gangliosides were spotted on a glass-backed
silica gel HPTLC plate after the 3-h 80 °C incubation in acid or
water. The plates were developed, and compounds were visualized by
immuno-overlay. Again, de-N-acetyl-GM3
maintained SMR36 reactivity after mild acid treatment (Fig.
2C), whereas the mild acid-treated GM3 was not
recognized by DH2 (Fig. 2B). As observed in the ELISA assay,
even the incubation of GM3 at 80 °C in water resulted in
significant Neu5Ac hydrolysis and reduction of DH2 reactivity. As an
important control, we also noted that mild acid treatment of
GM3 did not result in de-N-acetylation of the
Neu5Ac, which would have been detected by the antibody SMR36 (Fig.
2C).
Neuraminic Acid
-Methyl Glycoside Shows Similar Glycosidic
Linkage Stability under Acidic Conditions--
Studying the acid
hydrolysis of gangliosides is complicated by the fact that they form
micelles in aqueous solution. To obtain more direct proof of the
relative stability of the glycosidic linkage of neuraminic acid, we
used 1H NMR spectroscopy to analyze the acid hydrolysis of
the
-methyl glycoside of Neu (Neu
2Me, an analog of the sialic
acid in de-N-acetyl-GM3) at 80 °C as a
function of time. One-dimensional 1H NMR allowed us to
monitor the disappearance of the 2-O-methyl group and the
concomitant appearance of methanol, which would be produced upon
hydrolysis of the glycosidic linkage (see Fig. 3A). Because of the
interference that 2 M acetic acid produces in NMR, we
initially used hydrochloric acid at 10 mM, which had a pH
of 2.04 (2 M acetic acid, pH 2.08). The 1H NMR
spectrum of Neu
2Me in 10 mM HCl in D2O (Fig.
3A, bottom trace) showed the H-3ax and H-3eq
signals known to be characteristic for sialic acids (35); their
chemical shifts (see Table I) are
in agreement with involvement in
-glycosidic linkage. The triplet observed at
3.265 was assigned to Neu H-5 (by
two-dimensional 1H NMR experiments; results not shown); the
emergence of the H-5 signal from the envelope of other proton signals
(3.6 <
< 4.2) is due to the presence of the free amino
group at C-5. Finally, the signal for the 2Me group was observed at
3.376. Upon hydrolysis of Neu
2Me, we observed a decrease in
intensity of the 2Me signal, with a concomitant increase of a singlet
at
3.340. The latter signal arises from methanol
(CH3OD), one of the products of Neu
2Me hydrolysis. The
intensity ratio of the 2Me and methanol signals in the 1H
spectra at various times of exposure to 80 °C was taken as a measure
for extent of hydrolysis of the glycosidic linkage; the fraction of
intact glycoside is plotted as a function of heating time in Fig.
4. During the course of hydrolysis, the
other signals of Neu
2Me (including the H-3 and H-5 signals)
decreased in concert with the 2Me signal, whereas product signals
appeared (including those at 4.2 <
< 4.5, marked in
Fig. 3A). In this regard classic studies reported that free
Neu is unstable, undergoing a series of intra-molecular degradation
reactions in acidic conditions (17). We are currently pursuing the
structural characterization of the product(s) by NMR spectroscopy
and other methods.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
NMR spectroscopic analysis of the stability
of the glycosidic linkage of sialic acid
-methyl glycosides under acidic conditions.
1H NMR spectra of Neu 2Me (panel A) and
Neu5Ac 2Me (panel B) in 10 mM HCl were
obtained before (t = 0), and after incubation at
80 °C for the time periods indicated. The Sia reporter groups and
the signal for free methanol (produced by hydrolysis) are marked.
Signals labeled by asterisks (panel A) are
attributed to impurities in the Neu 2Me sample. The horizontal
brace (panel A) indicates new signals seen only after
exposure to acid and heat.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
1H chemical shifts of atoms used to monitor the hydrolysis of
sialic acid methyl glycosides
Chemical shifts are reported at 27 °C relative to TSP. At the
pH values of the D2O solutions used in this study (pH < 4), the methanol signal was found at 3.340. The methyl signal of
acetic acid (i.e. free acetate in acidic solution) was found
at 2.081, whereas the chemical shift of acetone was 2.217. ND, not
determined.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 4.
Kinetics of the acid hydrolysis of the
glycosidic linkage of sialic acid methyl glycosides. Panel
A, time course of cleavage of the glycosidic linkage of
Neu5Ac 2Me (circles) and Neu 2Me (squares) in
10 mM HCl at 80 °C. Panel B, time course of
glycosidic linkage hydrolysis of Neu 2Me in 0.1 M HCl
(circles) and in 1 M HCl (squares).
The degree of intactness of the methyl glycoside at a given time was
derived from the intensity ratio of the 2-O-methyl and
methanol signals in the corresponding 1H NMR spectra
(cf. Fig. 2).
|
|
For comparison, we monitored the hydrolysis of Neu5Ac
2Me in 10 mM HCl at 80 °C (Fig. 3B). The progress of
the conversion of the glycoside into methanol and free Neu5Ac was
traced by the decrease in intensity of the substrate 2Me, H-3eq, 5Ac,
and H-3ax signals and the concomitant appearance and increase in
intensity of methanol and of the H-3ax, H-3eq, and 5Ac signals at
1.880, 2.312, and 2.046, characteristic for free Neu5Ac in the
-configuration (35). Actually, Neu5Ac free in aqueous solution
occurs as a mixture of its
and
anomers in ratio 92:8; the minor
intensity H-3 and 5Ac signals of the
anomer are indeed visible in
the spectrum taken after 20 min (Fig. 3B, top
trace); their chemical shifts have been included in Table I. We
found that the 2-O-methyl signal decreased by 47% in the
Neu
2Me sample that had been treated in 10 mM HCl for
3 h at 80 °C (Fig. 3A). In contrast to this relative resistance to mild acid hydrolysis, the N-acetylated analog
Neu5Ac
2Me was 95% hydrolyzed in 10 mM HCl at 80 °C
after just 20 min (Fig. 3B). These data provide more solid
evidence that the conversion of the acetamido group at C-5 of sialic
acid to a free amino group confers stability to the glycosidic linkage
under acidic conditions.
It has been well established that glycosidic linkages in the equatorial
position of pyranoses are less stable than axial glycosidic linkages
(36, 37). We decided to test if this result held true for neuraminic
acid by comparing the
- and
-methyl glycosides (glycosidically
bound sialic acid in aqueous solution adopts the 2C5 conformation, where the
-glycosidic
linkage is equatorial, and the
is axial). Subjecting both methyl
glycosides to acid and heat revealed that the
-linked Neu was indeed
hydrolyzed at a significantly slower rate than the
-linked Neu. In
0.1 M HCl, Neu
2Me was 50% hydrolyzed after ~16 h at
80 °C (Fig. 4B), whereas Neu
2Me was close to 50%
hydrolyzed after 3 h at 80 °C in 10 mM HCl (Fig.
4A). Further studies are needed to identify the mechanism(s)
responsible for this observed difference. Regardless, these experiments
demonstrate that the
-glycosidic linkage of Neu is much more acid
stable than that of
-glycosidically linked Neu5Ac.
Glycosidically Linked Neuraminic Acid Can Be Hydrolyzed and
Detected after N-Acylation--
To date, there has been no chemical
proof of the presence of Neu in a ganglioside fraction that had not
been previously subjected to alkaline hydrolysis (which can
artifactually generate Neu from Neu5Ac). The primary reason for this
lack of proof is that naturally occurring de-N-acetylated
gangliosides are very minor components of complex mixtures of lipids.
We therefore applied our new knowledge of their relative acid stability
to develop a modified purification scheme. We reasoned that mild acid
treatment would degrade gangliosides containing N-acylated neuraminic
acid (and other acid-sensitive lipid species) in the biological lipid
extracts, while leaving the de-N-acetyl-gangliosides
relatively intact (and at the same time not artifactually generating
them). The surviving de-N-acetyl-gangliosides could then be
chemically N-acylated, rendering them sensitive to mild acid.
Amino sugars can be chemically N-acylated under the
appropriate conditions with several acyl-anhydrides (19, 38, 39). To
confirm that N-acylation of
de-N-acetyl-gangliosides restores an acid labile sialic
acid, we subjected mild acid pretreated de-N-acetyl-GM3 to acylation with acetic
anhydride or propionic anhydride using acetic acid or propionic acid as
controls. Subsequently, the samples were re-subjected to mild acid
hydrolysis, and the released sialic acids were derivatized with DMB.
The fluorescent peaks corresponding to the DMB derivatives of the
N-acylated sialic acids (sialic acid quinoxalinones, SiaQ)
are clearly resolved using reverse-phase HPLC for separation (Fig.
5, note that the starting
de-N-acetyl-GM3 preparation contains a small
amount of Neu5Ac that had survived the original
de-N-acetylation reaction). The area under the peak
corresponding to Neu5PrQ is within 7% of the area of the Neu5AcQ peak.
This demonstrates that glycosidically bound Neu5Ac and Neu5Pr are very
similar in their sensitivity to hydrolysis under mild acid
conditions.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 5.
HPLC analysis of sialic acids derived from
N-acylation of
de-N-acetyl-GM3.
De-N-acetyl-GM3 (80 ng) was treated with acetic
acid (HOAc), acetic anhydride
(Ac2O), propionic acid (HOPr),
or propionic anhydride (Pr2O) before mild
acid hydrolysis, DMB derivatization of released sialic acids, and C18
HPLC analysis with detection of the fluorescent adducts. Peaks
corresponding to DMB-derivatized Neu5Ac (Neu5AcQ) and Neu5Pr
(Neu5PrQ) are indicated with arrows. R
(reagent) indicates a fluorescent peak that forms independently of
sialic acids.
|
|
The molecular identity of the fluorescent adducts was confirmed by mass
spectrometry (as described under "Experimental Procedures"; data
not shown). Because Neu5Pr is not a naturally occurring form of sialic
acid, we reasoned that N-propionylation could be used for
tagging the free amino group of neuraminic acid on
de-N-acetyl-gangliosides. The addition of the
N-propionyl group not only allows subsequent mild acid
hydrolysis of the sialic acids but also gives a product of unique
molecular weight and HPLC retention time that can be easily
differentiated from any endogenous N-acylated sialic acids in biological samples that survive the initial hydrolysis.
Phospholipase C Can Be Used to Eliminate Phospholipids from Total
Lipid Extracts of Biological Origin--
Another formidable
challenge in the identification of de-N-acetyl-gangliosides
has been the physical dominance of contaminating phospholipids in total
lipid extracts. We have previously found that phospholipids interfere
with de-N-acetyl-ganglioside migration on HPTLC plates, with
their elution from DEAE-HPLC columns, and can block their recognition
by monoclonal antibodies.3 On the other hand, we found that
the typical phospholipid saponification procedures used in ganglioside
purification protocols will cause some chemical
de-N-acetylation (data not shown). Alternative methods utilizing two-phase solvent partitioning also pose a problem because of
unpredictable behavior of de-N-acetyl-gangliosides due to
the interactions with phospholipids.
To bypass these problems, we have developed an alternative approach to
degrade phospholipids enzymatically using a broad-spectrum PLC, which
also has activity against sphingomyelin (40). An example of the
degradation is shown in Fig. 6. Total
lipid extracts from B16 mouse melanoma tumors were treated with PLC
from Bacillus cereus, which results in significant but not
total degradation of phospholipids (Fig. 6, lane P).
Phospholipid degradation was enhanced by the addition of mild acid
treatment (Fig. 6, lane P/A).

View larger version (100K):
[in this window]
[in a new window]
|
Fig. 6.
Phospholipase and acid degradation of lipids
in biological extracts. HPTLC of total lipid extracts from B16
mouse melanoma cells that were untreated (U), incubated for
3 h at 80 °C in water (W), treated with PLC (100 milliunits) for 3 h at 37 °C (P), or treated with
PLC and then incubated for 3 h at 80 °C in 2 M
acetic acid (P/A). Phospholipids were visualized
using the phosphomolybdic acid spray reagent.
|
|
To further examine the validity of this approach, an aliquot of
synthetic de-N-acetyl-GD3 was spiked into a
total lipid extract from human kidney, and the extract was subjected to
PLC treatment and mild acid hydrolysis. Phospholipid head groups and
hydrolyzed N-acylated sialic acids were then eliminated
using a Microcon spin filter (3000 Da molecular mass cut-off). The
retentate was then recovered and treated with propionic anhydride to
N-propionylate the surviving de-N-acetyl sialic
acids. The newly N-propionylated sialic acids were now
susceptible to mild acid cleavage and could be isolated in the flow
through after spin filtration. After DMB derivatization, the SiaQ were
resolved by C18-HPLC with fluorescence detection and the NeuPr adduct
detected (data not shown). A human kidney extract that was not spiked
with synthetic de-N-acetyl-GD3 was
subjected to the same purification procedure in parallel with the spiked sample. The Neu5Pr adduct could not be detected in this
negative control. This indicates that Neu was not artifactually generated during the course of the purification.
Naturally Occurring Neuraminic Acid Can Be Identified in a Mild
Acid and Phospholipase C-treated Human Melanoma Lipid Extract--
We
next applied this new approach to search for
de-N-acetyl-gangliosides in several tissues and cell lines.
These included 25 different normal mouse tissue samples, human lung
(0.2 g) and kidney (0.5 g), a tumor of B16 mouse melanoma cells (0.5 g)
grown in nude mice (B16 cells have been reported to contain
de-N-acetyl-GM3) (5), U937 cells (0.2 g)
(reportedly containing cyclic sialic acid on glycoproteins, for which
Neu is the proposed precursor) (22), and three primary human melanomas
(0.2, 0.6, and 2.4 g) that were positive to varying degrees for
SGR37 reactivity.4 In our
hands, the three human tumors were the only samples for which we had
observed positive staining using the
anti-de-N-acetyl-ganglioside antibodies.
Of the 32 samples subjected to our purification scheme, one human
melanoma sample gave a fluorescent HPLC peak that co-eluted with the
DMB-derivatized Neu5Pr (Neu5PrQ) standard and was not present in the
propionic acid-treated control sample (Fig.
7A). Notably, this tumor was
the largest (2.4 g) and stained most intensely with SGR37 (data not
shown), which suggested that it would be the richest source of
de-N-acetyl-gangliosides. Fig. 7A shows two
traces, each representing 5% of tumor lipid extract. A significant amount of Neu5Ac appeared to be retained in the sample despite the acid
treatment and spin filtration. This may be because of the known
difficulty of taking the acid hydrolysis reaction to completion in
gangliosides (41). The fluorescent peak corresponding to Neu5PrQ from
human melanoma TB365 was subsequently isolated by subjecting 85% of
the extract to the purification procedure, with some minor changes to
accommodate the increase in lipid mass. Spin filtration units had a
tendency to clog easily, so dialysis was used to eliminate
N-acylated Sias after the first acid hydrolysis. Additionally, the second spin filtration was replaced with anion and
cation exchange as described under "Experimental Procedures" to
specifically isolate negatively charged molecules that had been
acid-released after propionic anhydride treatment.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Detection of Neu5Pr in a propionic
anhydride-treated lipid extract from a human melanoma tumor. A
total lipid extract from melanoma tumor TB365 was subjected to
sequential PLC and mild acid treatment as described under
"Experimental Procedures," dialyzed, and then subjected to
N-propionylation and sialic acid analysis. Panel
A, C18 HPLC elution profile of DMB adducts formed after treatment
with propionic anhydride (Pr2O) or
propionic acid (HOPr) and mild acid release. The peak
corresponding to Neu5PrQ is indicated with a circle.
Panel B, ESI ion-trap mass spectrum of the 34-39 min
fraction of the propionic anhydride treated TB365 sample. Panel
C, mass spectrometry profile after secondary collision-induced
dissociation of the m/z 440 ion in panel
B.
|
|
HPLC conditions were also altered to achieve better separation of
Neu5PrQ from other sialic acid adducts. Decreasing the acetonitrile concentration in the mobile phase from 8 to 7% resulted in increased retention time of Neu5PrQ (from ~22 to ~35 min) and improved
resolution of individual fluorescent peaks (data not shown). The
appropriate fraction (34-39 min) was collected as it eluted from
C18-HPLC and re-run on the HPLC. This second run was necessary because the prevalence of other sialic acid adducts in the sample caused some
HPLC column overloading. A fluorescent peak corresponding to Neu5PrQ
elution was clearly seen in the second C18-HPLC run of the TB365 sample
(data not shown). This peak was collected and run a third time on a
C18-HPLC column that feeds directly into the ion trap mass spectrometer
under the original mobile phase conditions (8% acetonitrile, 7%
methanol). A molecule co-eluting with the authentic Neu5Pr standard and
having a mass of 440 Da was detected (Fig. 7B). The identity
of the molecule was further confirmed by collision-induced
dissociation, which resulted in conversion to 422 Da (Fig.
7C). The loss of 18 mass units is typical of dehydration
seen in sialic acid quinoxalinones subjected to such secondary
bombardment (42). This represents the first chemical proof for the
presence of native Neu in a ganglioside fraction. Our inability to
detect Neu5Pr in many other samples processed in parallel to the
positive sample indicates that Neu is not being artifactually generated
over the course of our purification and work-up procedures but, rather,
occurs endogenously in detectable amounts only in this human melanoma.
It could still be argued that artifactual chemical generation of Neu is
only detectable in samples with the highest amount of sialic acids,
such as the positive melanoma. However, the lack of detectable Neu in
mouse brain serves as proof against this. Although the Neu5Pr-positive melanoma sample was somewhat larger in mass than the Neu5Pr negative mouse brain, the sialic acid content of the lipid fraction of these
samples is similar (only a 1.5-fold difference). Therefore, if Neu5Pr
in the melanoma arose from some unexpected artifact of chemical
de-N-acetylation occurring during the purification of sialic
acid rich samples, it would also have been detected in the mouse brain.
Very recently, another group studying heptafluorobutyrate derivatives
of acid-released sialic acids provided the first evidence of naturally
occurring Neu on a glycoprotein, ovine submaxillary mucin (23).
However, this study used traditional acid hydrolysis conditions for
release and, thus, may have underestimated the amount of Neu present.
In our current studies, we compared the overall amount of Neu5PrQ
detected to the amount of Neu5AcQ by assuming that the two forms of
sialic acid behave similarly with regard to efficiency of extraction,
extent of acid hydrolysis after N-acylation of Neu,
efficiency of DMB derivatization, and recovery on HPLC. Efficiency of
N-acylation reactions of Neu were also assumed to be similar
to those achieved for our standards (39%). Using these assumptions, we
calculate that Neu is about 0.06% of the Neu5Ac content in the total
lipid fraction of this human melanoma. Based on these calculations, we
concluded that purification of the intact ganglioside from this mixture
using current methodology would be extremely difficult. Our approach for purifying the soluble sugar has the advantage of selectively isolating small molecules that resist acid hydrolysis but can be
released by mild acid after treatment with propionic anhydride. This
specific set of criteria greatly minimizes other contaminants in the
preparation. Isolating and characterizing an intact
de-N-acetyl-ganglioside or its N-propionylated
form from biological samples will require further technological innovations.
Conclusions and Perspectives--
Here we have presented a
cautionary note regarding nonspecific cross-reactivity of a monoclonal
antibody thought to be specific for
de-N-acetyl-gangliosides, a novel finding regarding the acid stability of the glycosidic linkage of neuraminic acid, and a further
difference in this stability when comparing the
- and
-methyl
glycosides of the sugar. We have also used phospholipase C in
combination with mild acid treatment to eliminate contaminating lipid
species and definitively prove the existence of
de-N-acetyl-gangliosides. We obtained definitive evidence
for the existence of Neu by the following criteria: (a)
initial resistance to mild acid; (b) mild acid release after
N-propionylation; (c) DMB derivatization
(specific for
-keto acids); (d) HPLC fractionation (with
collection of fractions at the elution time specific for the Neu5Pr
product); (e) mass spectrometric proof for the Neu5Pr
product; (f) secondary mass spectrometric proof for the
Neu5Pr product; and (g) the absence of Neu5Pr in the
propionic acid treated control. The approaches presented in this paper
should be useful in future studies that seek proof of naturally
occurring neuraminic acid. Additionally, using PLC as a purification
tool for PL degradation will aid in the study of alkali labile
O-acetyl groups known to exist on some gangliosides in lipid extracts.
Despite these advances, the low level of expression of
de-N-acetyl-gangliosides pose daunting technical problems in
their purification and characterization. However, this low level does not argue against their biological importance. The in vitro
effects of adding synthetic de-N-acetyl-gangliosides have
been impressive and appear to be specific (5-7). There is also
accumulating evidence for the transient organization of gangliosides
into "glycosphingolipid-enriched microdomains" (GEMs) (43-45) or
into glycosylphosphatidylinositol-enriched "rafts" (46, 47)
within the plasma membrane. A recent report suggests that such
microdomain formation can correspond to a decreased threshold for
signaling in T-cells (48). Such a system would allow potentially potent
activators of signaling to exist in the membrane in an inactive state
of disorganization. However, upon raft assembly, local concentrations
of trace molecules like de-N-acetyl-gangliosides could be
elevated to effectual levels.
Exploration of such possibilities would be greatly aided by the
identification and cloning of the putative enzyme(s) responsible for
the de-N-acetylation. In preliminary studies, we have been unable to detect such an activity in extracts from tissues and cells
using a synthetic ganglioside analog. It is possible that the specific
substrate we are using is not recognized by the enzyme or that other
co-factors are needed. An alternative approach for isolating the
de-N-acetylase would be expression cloning.
De-N-acetyl-ganglioside-specific monoclonal antibodies are
available, and most cells express the precursor N-acetylated
gangliosides abundantly. Overall, de-N-acetyl-gangliosides remain a challenging but potentially important class of molecules for
further study.
 |
ACKNOWLEDGEMENTS |
We thank Sandra Diaz, Nissi Varki, and Roger
Chammas for help with some of the experiments and for helpful discussions.
 |
FOOTNOTES |
*
This work was supported by United States Public Health
Service Grants P01 CA58689 (to M. Farquhar) and R01-GM323373 (to
A. V.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: UCSD School of
Medicine 0687, La Jolla, CA 92093-0687. Tel.: 858-534-3296; Fax: 858-534-5611; E-mail: avarki@ucsd.edu.
Published, JBC Papers in Press, March 7, 2002, DOI 10.1074/jbc.M110867200
2
Ganglioside nomenclature is based on the
system of Svennerholm (41). GM3,
Neu5Ac
2,3Gal
1,4Glc
1,1-ceramide; GD3,
Neu5Ac
2,8Neu5Ac
2,3Gal
1,4Glc
1,1-ceramide; GM1,
Gal
1,3GalNAc
1,4(Neu5Ac
2,3)Gal
1,4Glc
1,1-ceramide.
3
R. Chammas and J. L. S., unpublished observations.
4
Nissi Varki, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
Neu, neuraminic
acid;
Neu5Ac, N-acetylneuraminic acid;
Neu5Ac
2Me, Neu5Ac
-methyl glycoside;
Neu5Gc, N-glycolylneuraminic acid;
Neu5Pr, N-propionylneuraminic acid;
Neu
2Me, neuraminic
acid
-methyl glycoside;
Neu
2Me, neuraminic acid
-methyl
glycoside;
CHO, Chinese hamster ovary;
DMB, 1,2-diamino-4,5-methylene
dioxybenzene;
ELISA, enzyme-linked immunosorbent assay;
HPTLC, high
performance thin layer chromatography;
HPLC, high performance liquid
chromatography;
mAb, monoclonal antibody;
PBS, phosphate-buffered
saline;
PLC, phospholipase C;
Sia, sialic acid, type unspecified;
SiaQ, sialic acid quinoxalinone (DMB adduct);
ESI, electrospray
ionization.
 |
REFERENCES |
| 1.
|
Hakomori, S.
(1981)
Annu. Rev. Biochem.
50,
733-764[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Zeller, C. B.,
and Marchase, R. B.
(1992)
Am. J. Physiol. Cell Physiol.
262,
1341-1355
|
| 3.
|
Stults, C. L. M.,
Sweeley, C. C.,
and Macher, B. A.
(1989)
Methods Enzymol.
179,
167-214[Medline]
[Order article via Infotrieve]
|
| 4.
|
Van Echten, G.,
and Sandhoff, K.
(1993)
J. Biol. Chem.
268,
5341-5344[Free Full Text]
|
| 5.
|
Hanai, N.,
Dohi, T.,
Nores, G. A.,
and Hakomori, S.
(1988)
J. Biol. Chem.
263,
6296-6301[Abstract/Free Full Text]
|
| 6.
|
Weis, F. M. B.,
and Davis, R. J.
(1990)
J. Biol. Chem.
265,
12059-12066[Abstract/Free Full Text]
|
| 7.
|
Zhou, Q.,
Hakomori, S.,
Kitamura, K.,
and Igarashi, Y.
(1994)
J. Biol. Chem.
269,
1959-1965[Abstract/Free Full Text]
|
| 8.
|
Nagai, Y.
(1995)
Behav. Brain Res.
66,
99-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Kasahara, K.,
Watanabe, Y.,
Yamamoto, T.,
and Sanai, Y.
(1997)
J. Biol. Chem.
272,
29947-29953[Abstract/Free Full Text]
|
| 10.
|
Cheresh, D. A.,
Pierschbacher, M. D.,
Herzig, M. A.,
and Mujoo, K.
(1986)
J. Cell Biol.
102,
688-696[Abstract/Free Full Text]
|
| 11.
|
Probstmeier, R.,
and Pesheva, P.
(1999)
Glycobiology
9,
101-114[Abstract/Free Full Text]
|
| 12.
|
Kojima, N.,
Shiota, M.,
Sadahira, Y.,
Handa, K.,
and Hakomori, S.
(1992)
J. Biol. Chem.
267,
17264-17270[Abstract/Free Full Text]
|
| 13.
|
Vyas, A. A.,
and Schnaar, R. L.
(2001)
Biochimie (Paris)
83,
677-682
|
| 14.
|
Markwell, M. A.,
Svennerholm, L.,
and Paulson, J. C.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
5406-5410[Abstract/Free Full Text]
|
| 15.
|
Walton, K. M.,
Sandberg, K.,
Rogers, T. B.,
and Schnaar, R. L.
(1988)
J. Biol. Chem.
263,
2055-2063[Abstract/Free Full Text]
|
| 16.
|
Karlsson, K.-A.
(1989)
Annu. Rev. Biochem.
58,
309-350[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Gottschalk, A.
(1960)
The Chemistry and Biology of Sialic Acids and Related Substances
, Cambridge University Press, Cambridge, UK
|
| 18.
|
Manzi, A. E.,
Sjoberg, E. R.,
Diaz, S.,
and Varki, A.
(1990)
J. Biol. Chem.
265,
13091-13103[Abstract/Free Full Text]
|
| 19.
|
Sjoberg, E. R.,
Chammas, R.,
Ozawa, H.,
Kawashima, I.,
Khoo, K.-H.,
Morris, H. R.,
Dell, A.,
Tai, T.,
and Varki, A.
(1995)
J. Biol. Chem.
270,
2921-2930[Abstract/Free Full Text]
|
| 20.
|
Chammas, R.,
Sonnenburg, J. L.,
Watson, N. E.,
Tai, T.,
Farquhar, M. G.,
Varki, N. M.,
and Varki, A.
(1999)
Cancer Res.
59,
1337-1346[Abstract/Free Full Text]
|
| 21.
|
Hidari, K. I.-P. J.,
Irie, F.,
Suzuki, M.,
Kon, K.,
Ando, S.,
and Hirabayashi, Y.
(1993)
Biochem. J.
296,
259-263[Medline]
[Order article via Infotrieve]
|
| 22.
|
Mitsuoka, C.,
Ohmori, K.,
Kimura, N.,
Kanamori, A.,
Komba, S.,
Ishida, H.,
Kiso, M.,
and Kannagi, R.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1597-1602[Abstract/Free Full Text]
|
| 23.
|
Zanetta, J. P.,
Pons, A.,
Iwersen, M.,
Mariller, C.,
Leroy, Y.,
Timmerman, P.,
and Schauer, R.
(2001)
Glycobiology
11,
663-676[Abstract/Free Full Text]
|
| 24.
|
Norgard-Sumnicht, K. E.,
Roux, L.,
Toomre, D. K.,
Manzi, A. E.,
Freeze, H. H.,
and Varki, A.
(1995)
J. Biol. Chem.
270,
27634-27645[Abstract/Free Full Text]
|
| 25.
|
Srikrishna, G.,
Toomre, D. K.,
Manzi, A.,
Panneerselvam, K.,
Freeze, H. H.,
Varki, A.,
and Varki, N. M.
(2001)
J. Immunol.
166,
624-632[Abstract/Free Full Text]
|
| 26.
| Moggridge, R. C. G., and Neuberger, A. (1938) J. Chem. Soc. 745-750
|
| 27.
|
Pukel, C. S.,
Lloyd, K. O.,
Travassos, L. R.,
Dippold, W. G.,
Oettgen, H. F.,
and Old, L. J.
(1982)
J. Exp. Med.
155,
1133-1147[Abstract/Free Full Text]
|
| 28.
|
Dohi, T.,
Nores, G.,
and Hakomori, S.
(1988)
Cancer Res.
48,
5680-5685[Abstract/Free Full Text]
|
| 29.
|
Nores, G. A.,
Hanai, N.,
Levery, S. B.,
Eaton, H. L.,
Salyan, E. K.,
and Hakomori, S.
(1988)
Carbohydr. Res.
179,
393-410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Nores, G. A.,
Hanai, N.,
Levery, S. B.,
Eaton, H. L.,
Salyan, M. E. K.,
and Hakomori, S.
(1989)
Methods Enzymol.
179,
242-252[Medline]
[Order article via Infotrieve]
|
| 31.
|
Magnani, J. L.,
Brockhaus, M.,
Smith, D. F.,
and Ginsburg, V.
(1982)
Methods Enzymol.
83,
235-241[Medline]
[Order article via Infotrieve]
|
| 32.
|
Hara, S.,
Yamaguchi, M.,
Takemori, Y.,
Furuhata, K.,
Ogura, H.,
and Nakamura, M.
(1989)
Anal. Biochem.
179,
162-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Lutz, M. S.,
Jaskiewicz, E.,
Darling, D. S.,
Furukawa, K.,
and Young, W. W., Jr.
(1994)
J. Biol. Chem.
269,
29227-29231[Abstract/Free Full Text]
|
| 34.
|
Varki, A.,
and Diaz, S.
(1984)
Anal. Biochem.
137,
236-247[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Haverkamp, J.,
van Halbeek, H.,
Dorland, L.,
Vliegenthart, J. F. G.,
Pfeil, R.,
and Schauer, R.
(1982)
Eur. J. Biochem.
122,
305-311[Medline]
[Order article via Infotrieve]
|
| 36.
|
Feather, M. S.,
and Harris, J. F.
(1965)
J. Org. Chem.
30,
153-157
|
| 37.
|
Collins, P. M.,
and Ferrier, R. J.
(1995)
Monosaccharides
, p. 73, John Wiley & Sons, Inc., New York
|
| 38.
|
Davidson, E. A.
(1966)
Methods Enzymol.
8,
52-60
|
| 39.
|
Collins, B. E.,
Fralich, T. J.,
Itonori, S.,
Ichikawa, Y.,
and Schnaar, R. L.
(2000)
Glycobiology
10,
11-20[Abstract/Free Full Text]
|
| 40.
|
Zwall, R. F. A.,
and Roelofsen, B.
(1974)
Methods Enzymol.
32,
154-161[Medline]
[Order article via Infotrieve]
|
| 41.
|
Svennerholm, L.
(1963)
J. Neurochem.
10,
613-623[Medline]
[Order article via Infotrieve]
|
| 42.
|
Klein, A.,
Diaz, S.,
Ferreira, I.,
Lamblin, G.,
Roussel, P.,
and Manzi, A. E.
(1997)
Glycobiology
7,
421-432[Abstract/Free Full Text]
|
| 43.
|
Iwabuchi, K.,
Handa, K.,
and Hakomori, S.
(1998) |